A PDGF receptor tyrosine kinase inhibitor, especially a
4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin--
2-ylamino)phenyl]-benzamide of the formula I 1
or a pharmaceutically acceptable salt thereof can be used in the treatment
of angiotensin II-induced diseases and a combination which comprises (a)
a PDGF receptor tyrosine kinase inhibitor preferably
N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-p-
yridyl)-2-pyrimidine-amine and (b) at least one compound selected from an
antihypertensive, an aldosterone antagonist, an aldosterone synthase
inhibitor and/or an angiotensin receptor blocker agent and optionally at
least one pharmaceutically acceptable carrier for simultaneous, separate
or sequential use, in particular for the treatment of hypertension and
hypertension-induced diseases.
